August"Based on its current cash burn rate, the Company anticipates that its existing cash balance is sufficient to fund operation through approximately August 2022. The Company will need to raise additional working capital through the sale of common shares, the issuance of debt or by entering into license or collaboration agreements to fund its operations and preclinical studies. The Company is actively pursuing financing sources in order to continue funding operations. As disclosed in the financial statements, these factors indicate the existence of a material uncertainty that may raise significant doubt about the Company’s ability to continue as a going concern."